Biocon Q4 FY26 preview: revenue, PAT, EBITDA range

What investors are tracking ahead of Q4 FY26

Biocon is expected to report its Q4 FY26 results in May 2026. The company has scheduled a board meeting to approve the audited consolidated financial statements for the quarter and the full year ended March 31, 2026. For market participants tracking the pharma and biosimilars space, the print matters because it will show whether Biocon can extend the sequential improvement seen in FY26.

Brokerages including MOFSL, YES Securities and JM Financial, along with others, have published preview estimates for the quarter. Their range of expectations clusters around revenue growth versus Q3 FY26 and a broadly steady operating margin profile. The street is also watching whether operating leverage and cost control keep profitability on track.

Q4 FY26 consensus: revenue, profit, and margins

Analyst estimates for Q4 FY26 revenue stand at Rs 4,000–4,300 crore. That compares with Rs 3,778 crore in Q3 FY26 (October to December 2025). The sequential step-up implied by the estimates is one of the central takeaways from the preview notes.

On profitability, analysts estimate profit after tax (PAT) of Rs 180–240 crore for Q4 FY26, versus Rs 141 crore in Q3 FY26. On operating performance, the expected EBITDA margin range is 24–27%, compared with 24.8% in Q3 FY26.

A key operational driver referenced in the preview commentary is the biosimilars franchise outside India. Growth momentum on the key volume or activity metric is projected at 15–20% for biosimilars in the US and Europe.

What changed versus Q3 FY26

Biocon’s Q3 FY26 numbers provide the immediate base for sequential comparisons. The company reported revenue of Rs 3,778 crore, PAT of Rs 141 crore, and EBITDA margin of 24.8% for the quarter.

The Q4 FY26 preview range suggests analysts are positioning for higher revenue and a similar-to-improving margin band. The PAT range of Rs 180–240 crore indicates expectations of improved profitability versus Q3 FY26, with operating leverage often cited as a supporting factor in the broker notes.

Board meeting agenda and dividend item

Alongside results approval, the May 2026 board meeting is also expected to consider a dividend. The preview information points to a dividend of Rs 0.50 per share (expected) at the Q4 FY26 board meeting.

Separately, the company had previously disclosed a final dividend of Rs 0.50 per share in the context of full-year reporting. Investors typically track whether dividend actions remain consistent with profitability and cash-flow priorities.

Stock levels: where Biocon is trading and targets

Biocon was trading around Rs 325 as of early April 2026. Over the last 52 weeks, the stock has been cited with a high of Rs 430 and a low of Rs 280.

The preview notes also reference analyst targets ranging from Rs 340 to Rs 360. These targets, paired with the upcoming results event, keep the stock on watchlists for investors focused on near-term earnings delivery.

Snapshot table: reported and estimated metrics

FY26 context from earlier quarters

Biocon’s FY26 started with Q1 FY26 operating revenue of Rs 3,942 crore, along with reported EBITDA margin disclosures including 21% on a like-for-like basis and a core operating margin of 25%. Q1 FY26 also included net R&D investments of Rs 205 crore, described as 7% of revenue ex-Syngene.

For Q2 FY26 (announced on November 11, 2025), Biocon reported consolidated revenue from operations of Rs 4,296 crore, with total revenue including other income of Rs 4,389 crore. The same disclosure cited EBITDA of Rs 928 crore with a 21% margin, and core EBITDA of Rs 1,218 crore with a 28% margin. Reported PAT for Q2 FY26 was Rs 85 crore, while PAT excluding exceptional items was Rs 92 crore.

What the Q4 print could clarify for the biosimilars narrative

The Q4 FY26 preview focuses on whether the company sustains momentum in biosimilars, especially in the US and Europe, where activity growth has been projected at 15–20%. If revenue lands within the estimated band and margins stay in the 24–27% range, it would align with expectations of continued execution through FY26.

At the same time, the wide PAT range highlights that investors are still sensitive to the translation of revenue growth into bottom-line outcomes. The market will likely parse the audited consolidated statements for confirmation of operating leverage, the cost base, and the quality of earnings that underpin PAT.

Market impact: what is priced in ahead of May 2026

With Biocon around Rs 325 in early April 2026 and targets at Rs 340–360, the market is clearly treating the May 2026 result as an important near-term checkpoint. The 52-week range of Rs 280–430 shows that the stock has already seen wide price swings, which can amplify the reaction to any deviation from the estimated revenue and PAT bands.

For investors focused on the pharma and biosimilars sector, the immediate indicators to track on results day are the revenue print versus Rs 4,000–4,300 crore, PAT versus Rs 180–240 crore, and the EBITDA margin outcome versus the 24–27% expectation.

Conclusion: the key numbers to watch

Biocon’s Q4 FY26 results, expected in May 2026, are set up as a material event for the stock given consensus expectations of Rs 4,000–4,300 crore in revenue and Rs 180–240 crore in PAT, with EBITDA margin projected at 24–27%. The board meeting is also expected to consider a Rs 0.50 per share dividend. Investors will watch the audited consolidated statements for confirmation of sequential growth from Q3 FY26 and the operating margin outcome against the preview range.